Colorectal cancer is the third commonest malignancy in UK with around 32 000 people diagnosed with colorectal cancer each year ([Cancerstats, 2003](#bib2){ref-type="other"}; [www.cancerresearchuk.org](http://www.cancerresearchuk.org)). Of that, around 20--25% of patients will have liver metastases (CRLM) at presentation and a further 40--50% will develop metachronous CRLM following colorectal surgery. Over the last two decades, liver resection has been established as the standard therapy for CRLM and offers the best chance of a potential cure with a 5-year survival of over 40% ([Finch *et al*, 2006](#bib7){ref-type="other"}; [Simmonds *et al*, 2006](#bib23){ref-type="other"}). However, disease recurrence is common with about two-thirds of patients who had liver resection for CRLM developing recurrent disease, and half of these patients had the disease recur in the remnant liver ([Steele *et al*, 1991](#bib24){ref-type="other"}; [Nordlinger *et al*, 1994](#bib19){ref-type="other"}; [Fong *et al*, 1997](#bib9){ref-type="other"}; [Hamady *et al*, 2006](#bib13){ref-type="other"}).

Several studies have looked for possible prognostic factors indicating poor survival outcome and disease recurrence after initial liver resection for CRLM ([Fong *et al*, 1999](#bib10){ref-type="other"}; [Seifert *et al*, 2000](#bib22){ref-type="other"}; [Takahashi *et al*, 2003](#bib25){ref-type="other"}; [Tanaka *et al*, 2004](#bib26){ref-type="other"}; [Hamady *et al*, 2006](#bib13){ref-type="other"}). Primary colorectal adenocarcinoma stage and grade, size, distribution and number of liver metastases, presence of extrahepatic disease, resection margins and lymph nodes status are among the potential prognostic factors but to date, no consensus have been reached.

Recently, there is increasing evidence that inflammation, both local and systemic, has a causal link in the pathogenesis of many solid tumours ([Balkwill and Mantovani, 2001](#bib1){ref-type="other"}; [Coussens and Werb, 2002](#bib5){ref-type="other"}). Infiltration of proinflammatory macrophages, cytokines and chemokines in the tumour microenvironment predispose the tumour to further progression, growth, invasion and metastasis. [Gunter *et al* (2006)](#bib12){ref-type="other"} showed an association between chronic low-grade inflammation, as evidenced by elevated C-reactive protein (CRP), with an increased risk of colorectal cancer. In addition, raised CRP is associated with an increased risk of developing early recurrence and poor outcome following colorectal surgery ([McMillan *et al*, 1995](#bib16){ref-type="other"}, [2003](#bib15){ref-type="other"}; [Canna *et al*, 2005](#bib3){ref-type="other"}). This suggests that it is not only the intrinsic properties of tumour cells that determine invasion and metastasis, but also the tumour microenvironment.

The aim of this study is to examine the relationship between inflammation, as evidenced by elevated CRP measured before surgery and outcome in patients who had liver resection for CRLM.

MATERIALS AND METHODS
=====================

Patients undergoing resection for colorectal liver metastases had CRP measured preoperatively. CRP (reference range being 10 mg l^−1^ or less) measurements were taken on the day before surgery with none of the patients showing clinical signs of sepsis. The criteria for acceptance for surgery included fitness for major resection and lack of disseminated or irresectable extrahepatic disease identified by computerised tomography (CT) or MRI scan. In all cases, the colorectal primary had been previously resected and the patients had recovered fully from that procedure. Patients who underwent neo-adjuvant therapy were excluded from this study. Intraoperative ultrasound was used as an adjunct to the preoperative radiological investigations. Resection was performed using the Cavi-Pulse Ultrasonic Surgical Aspirator (CUSA, Model 200 T, Valley Lab., Boulder, CO, USA). If necessary, an intermittent Pringle manoeuvre was used with 15 min of ischaemia followed by 5 min of reperfusion.

In accordance with our unit protocol, all patients undergoing liver resection were offered adjuvant therapy in the form of 5-FU/folinic acid, unless they had received adjuvant therapy following their colonic resection within the past one year.

Patients were followed up at specialist clinics, with a minimum follow-up period of 1 year at the time of writing (range 1−5 years; median 28 months). No patients were lost to follow-up. An intensive policy of postoperative surveillance exists within this unit. Patients have three monthly chest and abdominal CT performed during the first postoperative year, then 6 monthly during year 2. From year 3 to 5, a CT scan is performed yearly and finally at year 7 and year 10 of follow-up. Tumour markers carcinoembryonic antigen ((CEA), CA19-9) and liver function tests are performed during each clinic visit. The data examined included patient demographics; liver resection histology; prehepatectomy CEA and CA19-9 tumour marker; prehepatectomy CRP; postoperative morbidity/mortality results as well as recurrence and survival figures.

STATISTICS
==========

An SPSS version 9 statistical programme was used to analyse the data. The Student\'s *t*-test and χ^2^ tests were used to analyse differences among groups of patients with high or normal CRP. Where variables did not follow a normal distribution, the Mann--Whitney test was applied. Kaplan--Meier survival curves were used to analyse patient outcome. Patients who died in the postoperative period were excluded from the analysis of outcome. A Cox regression analysis was then performed in a step-wise manner in order to perform a multivariable analysis of clinico-pathological factors that impact both overall and disease-free survival.

RESULTS
=======

A total of 170 patients were included in this study. Of these patients, 106 (62%) were males and 64 (38%) females. The mean age of patient at time of surgery was 64 years (range 37--87 years; s.d. 9.86 years). A total of 86 (50.6%) patients had synchronous disease. All patients underwent liver resection. There were 76 (44.7%) patients who underwent an anatomical resection, a further 45 (26.5%) patients underwent a combination of anatomical and nonanatomical resection whereas the remaining 49 (28.8%) patients underwent a nonanatomical resection. A total of 57% of patients had a 'major\' (three or more Couinaud segments) resection performed. The in-hospital mortality rate was 3% and 29 (17%) patients had postoperative complications.

Preoperative CRP was elevated (\>10 mg l^−1^) in 54 (31.8%) patients. The differences in the clinico-pathological features of patients with a normal compared to an elevated CRP are presented in [Table 1](#tbl1){ref-type="table"}. Of note is that patients with an elevated CRP had no significant differences in the 'T\' or 'N\' stage of the primary tumour. However, patients with an elevated CRP tended to have larger metastases as well as increased CA19-9 levels compared to those with normal CRP.

Outcome
-------

Overall there were 80 (47%) patients who died during the time period of this study. Of these, there were six non-cancer-related deaths. Thus, the cancer-specific survival was 56%. The median survival of patients with an elevated CRP was 19 months (95% CI 7.5--31.2 months) compared to 42.8 months (95% CI 33.2--52.5 months) for those with a normal CRP, *P*=0.004 ([Figure 1](#fig1){ref-type="fig"}). Similarly, when assessing disease-free survival, patients with an elevated CRP had poorer disease-free survival (median of 11.8 months (95% CI 6.4--17.3) compared to median of 15.1 months (95% CI 11.1--19.1)), *P*=0.043 ([Figure 2](#fig2){ref-type="fig"}). The results of univariate and multivariable analysis of the predictors of overall survival are shown in [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"}, respectively. Of note is the fact that an elevated CRP was the only predictor of poor survival on univariate analysis. However on multivariable analysis, an elevated CRP as well as primary 'T\' stage both predicted for poorer overall survival. When the multivariable analysis was repeated for disease-free survival, only the presence of an elevated CRP predicted for poorer outcome, *P*=0.011 (HR 4.07; 95% CI 1.36--12.19).

DISCUSSION
==========

Tumour progression is a complex process that depends not only on the intrinsic properties of the tumour, but also on its interaction with the host cells. Although the link between inflammation and cancer was first proposed by Virchow in 1863, it is only in last two decades that we are beginning to delineate and have an understanding of this intricate network of interactions.

This study showed that elevated preoperative CRP present in almost one-third of patients with CRLM and is associated with a poor overall as well as disease-free survival in patients who had liver resection for colorectal metastases. This is consistent with other studies that found a positive correlation between elevated CRP concentrations, before surgery and a poor outcome in patients who had curative primary tumour resection ([Nozoe *et al*, 2001](#bib20){ref-type="other"}; [McMillan *et al*, 2003](#bib15){ref-type="other"}; [Canna *et al*, 2005](#bib3){ref-type="other"}; [Crumley *et al*, 2006](#bib6){ref-type="other"}). However, this is the first study to identify such a relationship among patients who have undergone curative resection for CRLM. This finding has important implications for selection of patients for surgery and the presence of an elevated CRP should be considered when counselling patients upon the likelihood of a 'curative resection\'.

We also found that elevated CRP was associated with presence of larger metastases size and elevated CA19-9. It is possible that any impact upon survival of an elevated CRP may be as a result of this association. However, as neither of these factors were independent predictors of survival on multivariable analysis, it appears that the elevated CRP is the main factor contributing to the poorer outcome among these patients. Interestingly, there was no association between 'T\' and 'N\' characteristics of the primary and an elevation in CRP.

The basis for the relationship between elevated CRP and poor prognosis is unclear and there are several possible explanations. Elevated CRP level may simply reflect a nonspecific inflammatory response to tumour necrosis or local tissue damage. Alternatively, it may be indicative of a favourable environment for the establishment and growth of distant metastases. Serum level of vascular endothelial growth factor (VEGF), an angiogenic factor, is increased in the presence of raised CRP concentration ([Xavier *et al*, 2006](#bib31){ref-type="other"}). Angiogenesis plays an important role in tumour growth and is associated with a poor outcome in patients with GI tumours ([Tanigawa *et al*, 1997](#bib27){ref-type="other"}; [Fondevila *et al*, 2004](#bib8){ref-type="other"}). In addition, interleukin (IL) -1 and -6 network is upregulated ([Vidal-Vanaclocha *et al*, 2000](#bib30){ref-type="other"}; [Miki *et al*, 2004](#bib17){ref-type="other"}). Interleukin 1 is involved in the development of metastasis in animal studies and IL-6, apart from being a growth factor, promotes resistance to apoptosis ([Vidal-Vanaclocha *et al*, 1994](#bib29){ref-type="other"}, [2000](#bib30){ref-type="other"}; [Chauhan *et al*, 1997](#bib4){ref-type="other"}; [Frassanito *et al*, 2001](#bib11){ref-type="other"}; [Jee *et al*, 2001](#bib14){ref-type="other"}). This creates a microenvironment that favours tumour angiogenesis, proliferation, growth and metastases.

Host immune response plays a role in the evolution of tumour growth. An impaired host immune response, evidenced by a weak lymphocyte infiltration at tumour margin, is associated with a poor prognosis in patients who had liver resection for CRLM ([Okano *et al*, 2003](#bib21){ref-type="other"}). There is an inverse relationship between CRP levels and tumour lymphocyte infiltration, with a raised CRP concentration indicative of a weak infiltration of lymphocytes at the periphery of the tumour ([Canna *et al*, 2005](#bib3){ref-type="other"}). The significance of systemic inflammatory response in the pathogenesis of cancer has important clinical implications.

Several novel therapies targeting the inflammatory pathways are in clinical trial ([Balkwill and Mantovani, 2001](#bib1){ref-type="other"}). Tumour necrosis factor (TNF) antagonists, chemokine and IL-6 antagonism, nonsteroidal anti-inflammatory agents and statin drugs are among the potential therapies. Selective Cox-2 inhibitors were of particular interest with promising initial results but adverse cardiovascular risks have limited their usage ([Mukherjee *et al*, 2001](#bib18){ref-type="other"}; [Thun *et al*, 2002](#bib28){ref-type="other"}; [Yau *et al*, 2003](#bib32){ref-type="other"}).

In summary, the results of this study showed that elevated CRP levels, measured before surgery, are present in a significant proportion of patients with CRLM. This is found to predict for a poor survival outcome in patients who had liver resection performed.
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###### 

Clinico-pathological features

  **Factor**                          **Normal CRP (10 mg l^−1^ or less) (*N*=116)**   **Elevated CRP (\>10 mg l^−1^) (*N*=54)**   **Significance**
  ---------------------------------- ------------------------------------------------ ------------------------------------------- ------------------
  Age (mean)                                               63.7                                          64.7                           0.577
  Synchronous disease                                       56                                            30                            0.502
  Male gender                                               73                                            33                            0.802
  Multiple (4 or more) metastases                           27                                            12                            0.568
                                                                                                                                           
  *Primary nodal status*                                                                                                                   
   N0                                                       32                                            10                            0.371
   N1                                                       51                                            27                               
   N2                                                       9                                              6                               
                                                                                                                                           
  *Primary T stage*                                                                                                                        
   T1                                                       1                                              3                            0.111
   T2                                                       8                                              3                               
   T3                                                       57                                            19                               
   T4                                                       24                                            15                               
                                                                                                                                           
  CEA                                                      61.5                                           63                            0.820
  CA19-9                                                   53.9                                          70.9                           0.013
  Large metastases size (\> 50 mm)                          34                                            31                            0.003
  Positive margin                                           23                                            15                            0.641

CEA=carcinoembryonic antigen; CRP=C-reactive protein. Mann--Whitney *U*-test.

###### 

Univariate analysis of overall survival

  **Factor**                  ***P*-value**
  -------------------------- ---------------
  Older age (years)               0.536
  Gender (males)                  0.522
  CEA                             0.353
  CA19-9                          0.838
  Large (\>50 mm)                 0.661
  metastases size                    
  Positive resection              0.461
  Margin                             
  Synchronous                     0.309
  disease                            
  Primary tumour                  0.754
  nodal positivity                   
  Poorer tumour                   0.124
  primary T-stage                    
  Multiple (4 or more)            0.244
  Metastases                         
  Poor clinical risk score        0.972
  Elevated CRP                   \<0.001

CEA=carcinoembryonic antigen; CRP=C-reactive protein. MSKCC clinical risk score -- poor scores defined as scores 3--5 ([Fong *et al*, 1999](#bib10){ref-type="other"}).

###### 

Multivariable analysis of overall survival

  **Factor**              **Hazard ratio (95% confidence interval)**   ***P*-value**  
  ---------------------- -------------------------------------------- --------------- -------
  Older age (years)                          1.04                       1.00--1.09     0.051
  Gender (males)                             1.09                       0.51--2.32     0.816
  CEA                                        0.99                       0.99--1.00     0.785
  CA19-9                                     0.99                       0.99--1.00     0.766
  Large (\>50 mm)                            0.99                       0.97--1.01     0.827
  metastases size                                                                         
  Positive resection                         0.56                       0.11--2.86     0.488
  Margin                                                                                  
  Synchronous                                0.92                       0.43--1.95     0.836
  disease                                                                                 
  Primary tumour                             0.60                       0.30--1.19     0.149
  nodal positivity                                                                        
  Poorer tumour                              1.82                       1.10--3.00     0.019
  primary T-stage                                                                         
  Multiple (4 or more)                       2.06                       0.91--4.66     0.785
  Metastases                                                                              
  Poor clinical risk                        0.707                       0.21--2.61     0.747
  score                                                                                   
  Elevated CRP                               2.86                       1.09--7.49     0.032

CEA=carcinoembryonic antigen; CRP=C-reactive protein. MSKCC clinical risk score-- poor scores defined as scores 3--5 ([Fong *et al*, 1999](#bib10){ref-type="other"}).
